Opthea's OPT-302: Advancing Novel Combination Therapy for Wet AMD
Background:
Opthea, a biopharmaceutical company specializing in retinal disease treatments, has been developing OPT-302 (sozinibercept), a first-in-class VEGF-C/D ‘trap’ designed to complement existing anti-VEGF-A therapies for wet Age-related Macular Degeneration (AMD). Wet AMD is a leading cause of vision loss in older adults, and while current treatments exist, there’s still a significant unmet need for more effective therapies.
Create a responsive, user-friendly website that simplifies complex clinical trial information, engages various user groups, and clearly presents Opthea's mission and progress in developing novel therapies for wet Age-related Macular Degeneration (AMD).
Opthea implemented a responsive web design with a clear, concise user experience focused on key information categories:
- Homepage Design:
- Clean, modern layout with a prominent hero section highlighting Opthea's mission
- Quick-access buttons for key sections like Clinical Trials and Investor Relations
- Clinical Trials Section:
- Interactive infographics explaining the OPT-302 mechanism of action
- Easy-to-navigate summaries of ongoing Phase 3 trials (ShORe and COAST)
- Investor Relations Portal:
- Real-time stock information widget
- Clearly organized financial reports and corporate governance documents
- Media Center:
- Responsive grid layout for press releases and news articles
- Embedded video content for visual engagement
- Mobile Optimization:
- Fully responsive design ensuring seamless experience across devices
- Touch-friendly navigation and collapsible menus for mobile users
- User-Centric Information Architecture:
- Conducted user research to identify key information needs for different stakeholders
- Organized content into logical, easy-to-navigate sections
- Visual Simplification:
- Used infographics and diagrams to explain complex scientific concepts
- Implemented a consistent color scheme aligned with Opthea's branding
- Performance Optimization:
- Optimized image sizes and implemented lazy loading for faster page speeds
- Used content delivery networks (CDNs) to ensure quick global access
- Improved User Engagement:
- 40% increase in average time on site
- 25% decrease in bounce rate
- Enhanced Mobile Experience:
- 50% increase in mobile traffic
- 30% improvement in mobile conversion rates for newsletter signups
- Increased Investor Interest:
- 35% growth in unique visitors to the Investor Relations section
- 20% increase in document downloads (annual reports, presentations)
- Simplified Information Access:
- 45% reduction in customer support inquiries about finding information
- Positive user feedback on the clarity of clinical trial explanations
Conclusion: The redesign of Opthea.com successfully transformed complex scientific content into an engaging, user-friendly experience. By focusing on responsive design, clear information architecture, and visual simplification, Opthea created a website that effectively serves the needs of its diverse audience while showcasing its innovative approach to treating wet AMD.
Next Steps: Opthea plans to further enhance the website by:
- Implementing A/B testing to continually refine user experience
- Developing an interactive patient education section
- Creating a secure portal for healthcare professionals to access detailed clinical data
